Patents by Inventor Ahmad Hashash

Ahmad Hashash has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stable SNS-595 compositions and methods of preparation
    Patent number: 9969730
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: May 15, 2018
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng
  • SALTS, CO-CRYSTALS, AND POLYMORPHS OF AN ANXIOLYTIC COMPOUND
    Publication number: 20170362230
    Abstract: The present invention provides crystalline Forms FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and related methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using a crystalline Form FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and/or pharmaceutical compositions thereof.
    Type: Application
    Filed: August 25, 2017
    Publication date: December 21, 2017
    Inventors: Bernard Luke FLYNN, Dharam PAUL, Andrew John HARVEY, Vasu V. SETHURAMAN, Raymond E. FORSLUND, Song XUE, Rob LIVINGSTON, Ahmad HASHASH
  • Salts, co-crystals, and polymorphs of an anxiolytic compound
    Patent number: 9745296
    Abstract: The present invention provides amorphous arid crystalline forms of 1-ethyl-6-(indan-2-ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co-crystals, and pharmaceutical compositions thereof. The invention also provides methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using the amorphous and crystalline forms, and salts, co-crystals, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 29, 2017
    Assignees: BIONOMICS LIMITED, IRONWOOD PHARMACEUTICALS, INC.
    Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey, Vasu V. Sethuraman, Raymond E. Forslund, Song Xue, Rob Livingston, Ahmad Hashash
  • STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION
    Publication number: 20170226104
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Application
    Filed: September 16, 2016
    Publication date: August 10, 2017
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng
  • Delayed Release Compositions of Linaclotide
    Publication number: 20160310559
    Abstract: The present invention relates to delayed release pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
    Type: Application
    Filed: December 11, 2014
    Publication date: October 27, 2016
    Inventors: Angelika Fretzen, Mark G. Currie, Ahmad Hashash, Mahendra Dedhiya, Yun Mo, Anil Chhettry, Matthew Miller, Ritesh Sanghvi, Mohammad Mafruhul Bari, Andreas Grill
  • Stable SNS-595 compositions and methods of preparation
    Patent number: 9469635
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: October 18, 2016
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng
  • Solid forms of an antiviral compound
    Patent number: 9409891
    Abstract: Crystalline solid forms and the amorphous form of the anti-HCV compound 5-(3,3-dimethylbutyn-1-yl)-3-[(cis-4-hydroxy-4-{[(3S)-tetrahydrofuran-3-yloxy]methyl}cyclohexyl){[(1R)-4-methylcyclohex-3-en-1-yl]carbonyl}amino]thiophene-2-carboxylic acid (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: August 9, 2016
    Assignee: GILEAD PHARMASSET LLC
    Inventors: Ahmad Hashash, Scott Wolckenhauer, Bing Shi
  • SALTS, CO-CRYSTALS, AND POLYMORPHS OF AN ANXIOLYTIC COMPOUND
    Publication number: 20160185770
    Abstract: The present invention provides amorphous arid crystalline forms of 1-ethyl-6-(indan-2-ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co-crystals, and pharmaceutical compositions thereof. The invention also provides methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using the amorphous and crystalline forms, and salts, co-crystals, and pharmaceutical compositions thereof.
    Type: Application
    Filed: March 14, 2014
    Publication date: June 30, 2016
    Inventors: Bernard Luke FLYNN, Dharam PAUL, Andrew John HARVEY, Vasu V. SETHURAMAN, Raymond E. FORSLUND, Song XUE, Rob LIVINGSTON, Ahmad HASHASH
  • SOLID FORMS OF AN ANTIVIRAL COMPOUND
    Publication number: 20140309187
    Abstract: Crystalline solid forms and the amorphous form of the anti-HCV compound 5-(3,3-dimethylbutyn-1-yl)-3-[(cis-4-hydroxy-4-{[(3S)-tetrahydrofuran-3-yloxy]methyl}cyclohexyl){[(1R)-4-methylcyclohex-3-en-1-yl]carbonyl}amino]thiophene-2-carboxylic acid (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.
    Type: Application
    Filed: June 24, 2014
    Publication date: October 16, 2014
    Inventors: Ahmad Hashash, Scott Wolckenhauer, Bing Shi
  • Solid forms of an antiviral compound
    Patent number: 8841340
    Abstract: Crystalline solid forms and the amorphous form of the anti-HCV compound 5-(3,3-dimethylbutyn-1-yl)-3-[(cis-4-hydroxy-4-{[(3S)-tetrahydrofuran-3-yloxy]methyl}cyclohexyl){[(1R)-4-methylcyclohex-3-en-1-yl]carbonyl}amino]thiophene-2-carboxylic acid (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: September 23, 2014
    Assignee: Gilead Sciences, Inc.
    Inventors: Ahmad Hashash, Scott Wolckenhauer, Bing Shi
  • STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION
    Publication number: 20140275547
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Application
    Filed: October 16, 2013
    Publication date: September 18, 2014
    Applicant: SUNESIS PHARMACEUTICALS, INC.
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Henggin Cheng
  • SOLID FORMS OF AN ANTIVIRAL COMPOUND
    Publication number: 20140051749
    Abstract: Crystalline solid forms and the amorphous form of the anti-HCV compound 5-(3,3-dimethylbutyn-1-yl)-3-[(cis-4-hydroxy-4-{[(3S)-tetrahydrofuran-3-yloxy]methyl}cyclohexyl){[(1R)-4-methylcyclohex-3-en-1-yl]carbonyl}amino]thiophene-2-carboxylic acid (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 20, 2014
    Inventors: Ahmad Hashash, Scott Wolckenhauer, Bing Shi
  • Stable SNS-595 compositions and methods of preparation
    Patent number: 8586601
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: November 19, 2013
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng
  • Salts of benzimidazolyl pyridyl ethers and formulations thereof
    Patent number: 8501785
    Abstract: Salts of benzimidazolyl pyridyl ethers are provided, particularly salts of {1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-(4-trifluoromethyl-phenyl)amine. Compositions and formulations including such salts and surfactants as well as methods of preparing such compositions and formulations are provided.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: August 6, 2013
    Assignee: Novartis AG
    Inventors: Rampurna Gullapalli, Ahmad Hashash, Piotr Karpinski, Kangwen L. Lin, Eric M. Loeser, Augustus O. Okhamafe, Paul Allen Sutton, Eduardo Sy
  • Formulations for benzimidazolyl pyridyl ethers
    Patent number: 8455662
    Abstract: Formulations are provided, comprising: a compound of Formula I, a pharmaceutically acceptable salt thereof, or a mixture of any two or more thereof; and an ingredient selected from a hydrophilic solvent, a lipophilic solvent, an emulsifier, or a mixture of any two or more thereof; wherein the compound of Formula I is: In some embodiments, the formulations are liquids. In other embodiments, the formulations are solids. Also provided are methods of preparing such formulations.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: June 4, 2013
    Assignee: Novartis AG
    Inventors: Ahmad Hashash, Sean Ritchie, Kangwen Lin, Peng Shen, Augustus Okhamafe, Rampurna Gullapalli
  • SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF
    Publication number: 20120308651
    Abstract: Salts of benzimidazolyl pyridyl ethers are provided, particularly salts of {1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-(4-trifluoromethyl-phenyl)amine. Compositions and formulations including such salts and surfactants as well as methods of preparing such compositions and formulations are provided.
    Type: Application
    Filed: June 4, 2012
    Publication date: December 6, 2012
    Inventors: Rampurna Gullapalli, Ahmad Hashash, Piotr H. Karpinski, Kangwen L. Lin, Eric M. Loeser, Augustus Okhamafe, Paul Allen Sutton, Eduardo Sy
  • Solid forms of a Raf kinase inhibitor
    Patent number: 8324389
    Abstract: The present invention is directed to solid forms of the Raf kinase inhibitor 1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine, as well as compositions thereof and uses of the same.
    Type: Grant
    Filed: February 28, 2008
    Date of Patent: December 4, 2012
    Assignee: Novartis AG
    Inventors: Ahmad Hashash, Kangwen L. Lin, Augustus O. Okhamafe
  • Salts of benzimidazolyl pyridyl ethers and formulations thereof
    Patent number: 8202998
    Abstract: Salts of benzimidazolyl pyridyl ethers are provided, particularly salts of {1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-(4-trifluoromethyl-phenyl)amine. Compositions and formulations including such salts and surfactants as well as methods of preparing such compositions and formulations are provided.
    Type: Grant
    Filed: August 30, 2007
    Date of Patent: June 19, 2012
    Assignee: Novartis AG
    Inventors: Rampurna Gullapalli, Ahmad Hashash, Piotr H. Karpinski, Kangwen L. Lin, Eric M. Loeser, Augustus Okhamafe, Paul Allen Sutton, Eduardo Sy
  • Stable SNS-595 compositions and methods of preparation
    Patent number: 8138202
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Grant
    Filed: December 30, 2010
    Date of Patent: March 20, 2012
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng
  • STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION
    Publication number: 20110086876
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Application
    Filed: December 30, 2010
    Publication date: April 14, 2011
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng